STOCK TITAN

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

(Positive)
Tags
partnership

IDEAYA Biosciences (NASDAQ: IDYA) announced a clinical collaboration with Roche to study IDE892, a Phase 1 MTA-cooperative PRMT5 inhibitor, with Roche’s pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma (PDAC).

IDEAYA will sponsor the trial; Roche supplies RG6505. Both companies retain commercial rights and oversee joint governance, with potential to add IDE397, IDEAYA’s MAT2A inhibitor, as a triplet regimen.

Loading...
Loading translation...

Positive

  • Clinical collaboration with Roche to evaluate IDE892 plus RG6505 in MTAP-deleted RAS-mutant PDAC
  • IDEAYA will sponsor the combination trial while Roche supplies RG6505
  • MTAP deletion occurs in up to 40% of PDAC, defining a sizable targeted subgroup
  • Collaboration allows potential triplet combination IDE892 + RG6505 + IDE397, expanding future study options

Negative

  • None.

News Market Reaction – IDYA

+1.90%
+1.90% Session close to close

In the Jun 3 session, IDYA gained 1.90%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds a Roche partnership around IDE892 in MTAP-deleted, RAS-mutant PDAC, targeting...
Analysis

This announcement adds a Roche partnership around IDE892 in MTAP-deleted, RAS-mutant PDAC, targeting a population where MTAP deletion occurs in up to 40% of cases and no targeted options exist. Combined with IDEAYA’s ongoing Phase 1 trial and plans for combination cohorts, it extends the company’s synthetic lethality strategy. Investors may track trial initiation, safety and efficacy readouts, and capital deployment under the existing automatic shelf registration filed on 2026-05-05.

Key Figures

MTAP deletion prevalence in PDAC: up to 40%
1 metrics
MTAP deletion prevalence in PDAC up to 40% Estimated frequency of MTAP deletion in pancreatic ductal adenocarcinoma

Historical Context

5 past events · Latest: Jun 01 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Jun 01 Registrational trial data Positive -1.8% Complete Phase 2/3 OptimUM-02 data showing efficacy and FDA RTOR review.
May 29 Inducement grants Neutral +0.4% Stock option grants to new hires under inducement plan at market price.
May 26 Conference participation Neutral +0.9% Jefferies Global Healthcare Conference fireside chat and AI panel appearances.
May 05 Earnings and pipeline Positive -0.3% Q1 2026 results with pivotal trial win and cash of $972.9M reported.
May 01 Inducement grants Neutral -3.1% Stock option grants to new employees at market price, 10-year term, four-year vesting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows positive clinical and financial updates sometimes met with mild share price declines, indicating a tendency toward selling into good news.

Recent Company History

Over the past months, IDEAYA reported multiple positive milestones, including strong Phase 2/3 darovasertib data and Q1 2026 results with $972.9M in liquidity, as well as repeated inducement option grants and conference participation. Notably, highly positive clinical and financial updates on May 5 and June 1 saw modest negative price reactions. This new Roche collaboration expands the MTAP-deletion strategy and fits the pattern of ongoing pipeline and partnership execution.

Key Terms

prmt5 inhibitor, pan-ras inhibitor, mtap deletion, pancreatic ductal adenocarcinoma, +1 more
5 terms
prmt5 inhibitor medical
"IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor"
A PRMT5 inhibitor is a drug that blocks the action of the enzyme PRMT5, which controls how some genes are turned on or off by tagging proteins inside cells. For investors, these drugs matter because they can slow or stop the growth of certain cancers and other diseases by reprogramming cell behavior, acting like a dimmer switch for disease-related genes; clinical trial results and approval decisions drive value and risk.
pan-ras inhibitor medical
"in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor"
A pan-RAS inhibitor is a drug designed to block activity of the RAS family of proteins (such as KRAS, NRAS and HRAS) that often drive uncontrolled cell growth in cancers. For investors, it matters because a single medicine that works across multiple RAS types can address a larger group of patients and reduce the risk that a tumor will bypass the drug, much like cutting power to several faulty switches instead of just one.
mtap deletion medical
"pancreatic ductal adenocarcinoma (PDAC) that carry an MTAP deletion"
mtap deletion is the loss of the MTAP gene from a cell’s DNA, which can happen in some cancers. For investors, it matters because that genetic gap often creates a predictable weakness drugs can target, making affected tumors both a potential market for specialized therapies and a marker used by companies to select patients for trials; think of it as a missing bolt that lets a tailored tool work more effectively.
pancreatic ductal adenocarcinoma medical
"in patients with pancreatic ductal adenocarcinoma (PDAC) that carry an MTAP deletion"
A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.
nsclc medical
"in PDAC with RG6505 as well as in NSCLC and other solid tumors"
NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma
  • IDEAYA will sponsor the clinical trial, and there will be joint IDEAYA and Roche governance to oversee the study
  • MTAP-deletion is estimated to occur in up to 40% of PDAC

SOUTH SAN FRANCISCO, Calif., June 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration with Roche to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class PRMT5 inhibitor, in combination with Roche's RG6505, a pan-RAS inhibitor, in patients with pancreatic ductal adenocarcinoma (PDAC) that carry an MTAP deletion. IDEAYA will sponsor the clinical trial combination study, and Roche will supply RG6505.

"We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. "This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high unmet need in PDAC." 

IDE892 was designed to be a potential best-in-class PRMT5 inhibitor and has demonstrated robust monotherapy regressions in MTAP-deleted preclinical models. IDEAYA is evaluating IDE892 in a Phase 1 dose escalation clinical trial in MTAP-deleted solid tumors and plans to initiate Phase 1 combination cohorts, in PDAC with RG6505 as well as in NSCLC and other solid tumors with IDE397, IDEAYA's proprietary MAT2A inhibitor.

MTAP deletion is estimated to occur in up to 40% of PDAC and almost all MTAP-deleted PDAC harbor co-occurring RAS mutations. Combining a PRMT5 inhibitor with a pan-RAS inhibitor may have the potential to drive deeper and more durable responses for MTAP-deleted PDAC patients who currently have no approved targeted treatment options. 

Under the clinical collaboration, IDEAYA and Roche each retain all commercial rights to their respective compounds, including as monotherapy and as combination therapies. There will be joint IDEAYA and Roche governance to oversee the clinical combination study. The clinical collaboration also has the ability to evaluate a combination triplet with IDE892, RG6505, and IDE397, IDEAYA's Phase 2 MAT2A inhibitor, upon joint IDEAYA and Roche approval.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the potential therapeutic benefit, safety, and efficacy of IDE892, alone or in combination with RG6505; the planned clinical development, including the initiation, timing, progress, and design of clinical trials evaluating IDE892 in combination with RG6505 and other agents; the potential for IDE892 to be a best-in-class PRMT5 inhibitor; the potential for combination therapies targeting MTAP-deleted and RAS-mutant tumors to drive deeper or more durable responses; the estimated prevalence of MTAP deletions in PDAC; the potential benefits of the clinical collaboration with Roche; and IDEAYA's broader clinical and strategic plans, including the development of its MTAP-deletion portfolio. Such forward-looking statements are based on IDEAYA's current expectations and beliefs and involve substantial risks and uncertainties that could cause actual results to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, but are not limited to: risks related to the success, cost, and timing of IDEAYA's product candidate development activities and clinical trials; the risk that results from preclinical studies or early clinical trials may not be predictive of future clinical results; risks related to the development and regulatory approval of drug candidates; risks related to IDEAYA's dependence on third parties, including Roche, for collaboration activities and clinical supply; risks related to the ability to successfully enroll patients in clinical trials; and risks related to the potential for adverse safety events or lack of efficacy. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed or implied by the from these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Annual Report on Form 10-K dated February 17, 2026, and any current and periodic reports filed or furnished with the Securities and Exchange Commission.

Investor and Media Contact

IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-clinical-collaboration-with-roche-in-mtap-deleted-ras-mutant-pancreatic-cancer-302789169.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What clinical collaboration did IDEAYA (NASDAQ: IDYA) announce with Roche on June 3, 2026?

IDEAYA announced a clinical collaboration with Roche to evaluate IDE892 plus RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. According to IDEAYA, it will sponsor the trial while Roche supplies RG6505, and both companies will oversee the study through joint governance.

What is IDE892 and how will it be studied with RG6505 in MTAP-deleted RAS-mutant PDAC?

IDE892 is IDEAYA’s investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor currently in Phase 1 development. According to IDEAYA, it will be combined with Roche’s Phase 1 pan-RAS inhibitor RG6505 in patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma to assess safety and efficacy.

How common is MTAP deletion in pancreatic ductal adenocarcinoma and why is it important for IDYA?

MTAP deletion is estimated to occur in up to 40% of pancreatic ductal adenocarcinoma cases. According to IDEAYA, almost all MTAP-deleted PDAC also carry RAS mutations, creating a defined subgroup for targeted combinations like IDE892 with RG6505 in its MTAP-deletion portfolio.

What are IDEAYA Biosciences' plans for IDE892 combination trials beyond PDAC?

IDEAYA plans to evaluate IDE892 in Phase 1 dose escalation for MTAP-deleted solid tumors and initiate combination cohorts. According to IDEAYA, combinations will include IDE892 with RG6505 in PDAC and with IDE397, its MAT2A inhibitor, in non-small cell lung cancer and other solid tumors.

Who holds commercial rights to IDE892 and RG6505 in the IDEAYA and Roche collaboration?

Each party retains full commercial rights to its own compound under the collaboration. According to IDEAYA, it keeps rights to IDE892 and IDE397, while Roche retains rights to RG6505, both as monotherapies and in combination regimens arising from the clinical study.

Could IDEAYA and Roche study a triplet regimen with IDE892, RG6505 and IDE397 for MTAP-deleted PDAC?

The collaboration provides the option to evaluate a triplet of IDE892, RG6505 and IDE397. According to IDEAYA, any triplet cohort would proceed upon joint IDEAYA and Roche approval, potentially extending combination strategies for MTAP-deleted pancreatic ductal adenocarcinoma and related solid tumors.